Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of LY3209590 Formulations in Healthy Participants
NCT04768842Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2021
- Primary completion
- Sep 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration and Area Under the Concentration Versus Time Curve from Time Zero to Infinity. Started Mar 2021; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04768842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768842.